Clinical Trials Logo

Clinical Trial Summary

Primary hyperaldosteronism confers a higher risk of cardiovascular complications compared to essential hypertension. Preliminary data is controversial in regards of excessive maternal fetal and neonatal excessive risks in pregnancy. This study aims at establishing the prevalence of PHA in an population with a recent episode of hypertensive disorder of pregnancy (HDP). The goal is to determine if a universal screening for PHA after a HDP is worthed. The investigators also wish to evaluate the complication rate in pregnant women with PHA compared to women without PHA. This is a prospective cohort study where all eligible women will be screened for PHA after a HDP episode in the last pregnancy. We will then compare PHA women to non PHA women according to pregnancy complications.


Clinical Trial Description

This is a pilot study to evaluate feasibility and proof of concept. This is a prospective multicenter cohort study. Two university centers will participate (Sherbrooke and Montreal). Participants will be recruited from post-partum Obstetric Medicine clinic in two tertiary care centers. They will be included if they presented a hypertensive disorder of preganncy (HDP) in their last pregnacy (from 4 weeks to 24 months after delivery). Women with pheochromocytoma, Cushing syndrome, secondary hyperaldosteronism, and those who are currently pregnant will be excluded. All participants will be screened for PHA (with an aldosterone/renin ratio) and if the screening test is positive, they will be referred to a specialist to confirm the diagnosis. Data will be collected from the participants and their babies' charts. Demographic data, obstetrical data, delivery data, maternal/fetal/neonatal complications, and diagnostic of PHA data will be collected. A convenient sample size of 200 women will be used. If the prevalence of HPA is 5% or more, this would justify a larger study. Primary outcome: establish the prevalence of PHA in women with a hypertensive disorders of pregnancy in last pregancy. Secondary outcome include: 1. to compare maternal, fetal and neonatal outcomes among women diagnosed with primary hyperaldosteronism (PHA) and pregnant women without PHA. 2. to establish the prevalence of PHA for each sub-type of hypertensive disorder of pregnancy 3. to compare maternal, fetal and neonatal outcomes among women diagnosed with primary hyperaldosteronism (PHA) before pregnancy and pregnant women diagnosed with PHA after pregnancy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05636995
Study type Observational [Patient Registry]
Source Université de Sherbrooke
Contact Nadine Sauvé, MD
Phone 819-346-1110
Email nadine.sauve@usherbrooke.ca
Status Recruiting
Phase
Start date January 10, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT05687344 - Intensive Postpartum Antihypertensive Treatment Phase 3
Recruiting NCT02020174 - The Preeclampsia Registry
Recruiting NCT06377878 - The Preeclampsia Registry
Recruiting NCT05995106 - mHealth for Hypertensive Disorder of Pregnancy N/A
Completed NCT03309826 - Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing in Hypertensive Disorders of Pregnancy N/A
Completed NCT05631067 - Feasibility and Acceptability of Risk Stratification in the Fourth Trimester to Reduce Maternal Morbidity and Mortality N/A
Completed NCT03412552 - Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia N/A
Completed NCT03728790 - Remote BP Monitoring in the PP Period N/A
Recruiting NCT05089175 - The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population
Enrolling by invitation NCT05763069 - HOME: Home Monitoring of High-risk Pregnancies
Recruiting NCT06069102 - Optimal Blood Pressure Treatment Thresholds Postpartum Phase 4
Recruiting NCT05659173 - Vitamin D Deficiency With Selected Vitamin D Receptor Gene Polymorphism in Gestational Hypertension
Recruiting NCT06281665 - Treatment With Aspirin After Preeclampsia: TAP Trial Phase 4
Completed NCT05124327 - Remote Monitoring and Follow-up for Postpartum Hypertensive Disorders of Pregnancy N/A
Recruiting NCT06362356 - Microbial Metabolites and Outcomes of Pregnancy Study
Active, not recruiting NCT04580927 - Breastfeeding and Postpartum Cardiovascular Health N/A
Recruiting NCT05655936 - Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial N/A
Enrolling by invitation NCT05835596 - MumCare: Mum's Cardiovascular Health for Life N/A
Completed NCT06019715 - Remote Postpartum Intervention Targeting Movement Behaviors After Hypertensive Disorders of Pregnancy N/A